*Sponsored message*
In the initial Phase 3 trial, a 12-month results did not meet the primary endpoint. However did meet primary endponts following post-hoxk analysis. Furthermore, treatment with Topical Patidegib Gel 2% demonstrated a favorable safety profile, with none of the adverse effects commonly associated with oral hedgehog inhibitors—no significant hair loss, taste disturbances, or muscle cramps, and no irritation comparable to imiquimod or 5-fluorouracil (5-FU).
Key Findings from the First Phase 3 Trial:

• There was a 30% reduction in new facial basal cell carcinomas (BCCs) compared to those using the vehicle.
• Post-hoc subset analysis in patients with a PTCH1 mutation and a higher baseline burden of facial BCCs showed an even greater effect—a 50% reduction in new facial BCCs (p < 0.01).

 The Next Phase 3 Trial: Targeted Inclusion Criteria
Given these promising results, the new trial is enrolling Gorlin syndrome patients who meet the following criteria: 

1. Confirmed clinical diagnosis of Gorlin syndrome
2. Presence of a PTCH1 mutation
3. Higher baseline burden of facial BCCs

While we have successfully enrolled a significant number of participants, greater enrollment increases the likelihood of replicating the positive findings from the subset analysis in the first trial. Unfortunately, many Gorlin syndrome patients remain unaware of this trial and its potential benefits.

Call to Action
We urge you to inform your Gorlin syndrome patients and their affected relatives about this important study.
For more details, including a list of  clinical sites across the USA, please visit ClinicalTrials.gov (NCT06050122) or contact Sol-Gel  at clinicalinfo@sol-gel.com.
For direct inquiries, feel free to reach out to me: 510-502-6144 | eepsteinjr@aol.com

Find eurpoean centers below
 
A Personal Note
As a consultant to the sponsor of this second Phase 3 trial and a co-founder of the company that initiated this research, I strongly believe that Topical Patidegib Gel 2% has the potential to transform the lives of Gorlin syndrome patients, much like the development of Erivedge and Odomzo has done. Your support in raising awareness and encouraging participation will be deeply appreciated by the entire Gorlin syndrome community.

Thank you for your time and assistance!
Ervin Epstein, MD
Consultant to Sol-Gel

France

Bobigny – Hopital Avicenne
+33 1 48 95 70 48 | isabelle.scheer@aphp.fr

Nantes – Centre Hospitalier Universitaire De Nantes
+33 2 40 08 31 31 | caroline.monfort@chu-nantes.fr

Pierre-Bénite – Centre Hospitalier Lyon Sud
+33 4 78 86 33 35 | caroline.marchi@chu-lyon.fr

Germany

Berlin – Charité Universitätsmedizin Berlin - Campus Charité Mitte
+49 30 450 518448 | Nurcan.Uzun@charite.de

Chemnitz – DRK Gemeinnützige Krankenhaus GmbH Sachsen
+49 371 8325003 | nowaczyk.joanna@drk-khs.de

München, Bayern – Ludwig-Maximilians-Universität München (LMU) – Klinik und Poliklinik für Dermatologie und Allergologie
+49 89 4400 56326 | DER.onko.studien@med.uni-muenchen.de

Italy

Brescia – ASST Spedali Civili di Brescia
+39 030 399 5302 | piergiacomo.calzavarapinton@unibs.it

Novara – AOU Maggiore della Carità
+39 0321 3733269 | elisa.zavattaro@med.uniupo.it

Rome – Fondazione Policlinico Universitario Agostino Gemelli IRCCS
+39 06 3015 8620 | francescobrunetti96@gmail.com

Netherlands

Maastricht – Maastricht University Medical Center
onderzoek.dermatologie@mumc.nl

Spain

Barcelona – Hospital Clinic Barcelona
+34 93 227 54 00 (ext. 4622) | piglesia@recerca.clinic.cat

Barcelona – Hospital de la Santa Creu i Sant Pau
+34 93 553 70 07 | VRuizS@santpau.cat

Madrid – Hospital Universitario 12 De Octubre
+34 91 779 22 61 | carmenmaria.garcia.imas12@h12o.es

United Kingdom

Birmingham – The University of Birmingham
+44 121 371 8750 | Jessica.Bayliss@uhb.nhs.uk

London – Barts Health NHS Trust - The Royal London Hospital
+44 20 3594 3327 / 3328 / 3326 | nikka.bautista@nhs.net

Salford – Northern Care Alliance NHS Foundation Trust
+44 161 206 0893 | Priscillia.Mbalisike@manchester.ac.uk